/ALKS
ALKS Stock - Alkermes plc
Healthcare|BiotechnologyNASDAQ
$28.45+2.30%
+$0.64 (+2.30%) • Dec 19
74
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.36
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+66.6%upside
Target: $47.40
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ALKS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$28.17 – $28.73
TARGET (TP)$47.40
STOP LOSS$26.17
RISK/REWARD1:8.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.44
52W High$36.45
52W Low$25.17
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.56B | $1.66B | $1.11B | $1.17B | $1.04B |
| Gross Profit | $1.31B | $1.41B | $893.73M | $976.43M | $860.44M |
| Gross Margin | 84.2% | 84.8% | 80.4% | 83.2% | 82.8% |
| Operating Income | $420.64M | $414.12M | $-6,089,000 | $97.75M | $-112,427,000 |
| Net Income | $367.07M | $355.76M | $-158,267,000 | $-48,169,000 | $-110,861,000 |
| Net Margin | 23.6% | 21.4% | -14.2% | -4.1% | -10.7% |
| EPS | $2.22 | $2.14 | $-0.97 | $-0.30 | $-0.70 |
Company Overview
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
12
67%
Hold / Neutral
5
28%
Sell / Underperform
1
6%
Analyst Consensus🟡 Mixed
12 Bullish6 Neutral/Bearish
Price Targets
$37
Average Target
↑ 28.8% Upside
Now
$25
Low
$37
Average
$50
High
Based on 20 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 11th 2025 | Truist | Initiation | Buy | $50 |
| September 26th 2025 | RBC Capital Mkts | Upgrade | Outperform | $44 |
| September 3rd 2025 | Wells Fargo | Initiation | Overweight | $44 |
| July 15th 2025 | Goldman | Initiation | Buy | $43 |
| June 17th 2025 | UBS | Upgrade | Buy | $42 |
| May 28th 2025 | Needham | Initiation | Buy | $45 |
| March 13th 2025 | RBC Capital Mkts | Initiation | Sector Perform | $40 |
| March 4th 2025 | UBS | Upgrade | Neutral | $38← $21 |
| February 11th 2025 | Deutsche Bank | Initiation | Buy | $40 |
| November 5th 2024 | Stifel | Upgrade | Buy | $36← $25 |
| June 17th 2024 | TD Cowen | Initiation | Buy | $34 |
| March 19th 2024 | Robert W. Baird | Initiation | Outperform | $37 |
| February 20th 2024 | UBS | Downgrade | Sell | $25 |
| November 20th 2023 | JP Morgan | Resumed | Neutral | $33 |
| October 24th 2023 | Evercore ISI | Upgrade | Outperform | - |
Earnings History & Surprises
ALKSBeat Rate
72%
Last 18 quarters
Avg Surprise
+138.2%
EPS vs Estimate
Beats / Misses
13/4
1 met exactly
Latest EPS
$0.49
Q4 2025
EPS Surprise History
Q1 24
+4.3%
$0.48vs$0.46
Q2 24
-25.4%
$0.44vs$0.59
Q3 24
0.0%
$0.70vs$0.70
Q4 24
-2.7%
$0.72vs$0.74
Q1 25
+28.4%
$1.04vs$0.81
Q2 25
-48.9%
$0.13vs$0.25
Q3 25
+26.8%
$0.52vs$0.41
Q4 25
+16.7%
$0.49vs$0.42
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 11, 2026 | $0.43 | — | — | — |
Q4 2025 | Oct 28, 2025 | $0.42 | $0.49 | +16.7% | ✓ BEAT |
Q3 2025 | Jul 29, 2025 | $0.41 | $0.52 | +26.8% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $0.25 | $0.13 | -48.9% | ✗ MISS |
Q1 2025 | Feb 12, 2025 | $0.81 | $1.04 | +28.4% | ✓ BEAT |
Q4 2024 | Oct 24, 2024 | $0.74 | $0.72 | -2.7% | ✗ MISS |
Q3 2024 | Jul 24, 2024 | $0.70 | $0.70 | 0.0% | = MET |
Q2 2024 | May 1, 2024 | $0.59 | $0.44 | -25.4% | ✗ MISS |
Q1 2024 | Feb 15, 2024 | $0.46 | $0.48 | +4.3% | ✓ BEAT |
Q4 2023 | Oct 25, 2023 | $0.44 | $0.64 | +45.5% | ✓ BEAT |
Q3 2023 | Jul 26, 2023 | $0.48 | $0.55 | +14.6% | ✓ BEAT |
Q2 2023 | Apr 26, 2023 | $0.00 | $0.01 | +174.0% | ✓ BEAT |
Q1 2023 | Feb 16, 2023 | $0.05 | $0.14 | +180.0% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $0.03 | $0.02 | -34.1% | ✗ MISS |
Q3 2022 | Jul 27, 2022 | $0.01 | $0.06 | +740.3% | ✓ BEAT |
Q2 2022 | Apr 27, 2022 | $0.01 | $0.12 | +1066.2% | ✓ BEAT |
Q1 2022 | Feb 16, 2022 | $0.13 | $0.23 | +76.9% | ✓ BEAT |
Q4 2021 | Oct 27, 2021 | $0.08 | $0.14 | +75.0% | ✓ BEAT |
Q3 2021 | Jul 28, 2021 | $0.12 | $0.30 | +150.0% | ✓ BEAT |
Latest News
Alkermes To Acquire Avadel Pharmaceuticals In Shareholder Scheme, Sends Proposal To Equity And Employee Share Purchase Plan Holders
📉 NegativeBenzinga•Dec 5, 2025, 09:03 PM•Also:
AVDL stock has given up its prior gain. Avadel Pharmaceuticals shares were trading higher after Alkermes increased the buyout offer to up to $22.50 per share.
➖ NeutralBenzinga•Nov 19, 2025, 11:42 AM•Also:
Avadel Pharmaceuticals shares are trading higher after Alkermes increased the buyout offer to up to $22.50 per share.
📈 PositiveBenzinga•Nov 19, 2025, 11:06 AM•Also:
Alkermes Has Increased The Buyout For Avadel Pharmaceuticals To Up To $22.50 Per Share, Consisting Of $21.00 In Cash And 1 Contingent Value Right Of Additional Cash Payment Of $1.50 Per Share
📈 PositiveBenzinga•Nov 19, 2025, 11:02 AM•Also:
Truist Securities Maintains Buy on Alkermes, Raises Price Target to $55
📈 PositiveBenzinga•Nov 17, 2025, 01:25 PM
Avadel Pharmaceuticals' Board Of Directors Has Determined That The Unsolicited Proposal From H. Lundbeck Constitutes A "Company Superior Proposal" Over The Existing Transaction Agreement With Alkermes
📈 PositiveBenzinga•Nov 17, 2025, 10:47 AM•Also: ,
Alkermes Says It Is Considering Options After Avadel Discloses Possible Lundbeck Offer And Highlights Avadel's Ongoing Obligation To Negotiate Under Existing Transaction Agreement
➖ NeutralBenzinga•Nov 14, 2025, 12:47 PM•Also:
Avadel climbs as Lundbeck outbids Alkermes in latest bidding war
📈 PositiveSeeking Alpha•Nov 14, 2025, 11:57 AM•Also:
Avadel Board Says Lundbeck Proposal May Be A Company Superior Proposal While Keeping Support For Existing Alkermes Deal Offering Up To $20 Per Share
➖ NeutralBenzinga•Nov 14, 2025, 10:51 AM•Also:
Wells Fargo Maintains Overweight on Alkermes, Lowers Price Target to $37
➖ NeutralBenzinga•Nov 13, 2025, 03:43 PM
Deutsche Bank Maintains Buy on Alkermes, Lowers Price Target to $45
➖ NeutralBenzinga•Nov 13, 2025, 11:38 AM•Also:
Truist Securities Reiterates Buy on Alkermes, Maintains $50 Price Target
📈 PositiveBenzinga•Nov 12, 2025, 06:15 PM
Alkermes falls after mid-stage trial data for sleep therapy
📉 NegativeSeeking Alpha•Nov 12, 2025, 02:01 PM
Alkermes Data From Vibrance-2 Phase 2 Trial Of Alixorexton In Participants With narcolepsy type 2 Meets Dual Primary Endpoints, Demonstrates Statistically Significant, Clinically Meaningful Improvements In Wakefulness, Excessive Daytime Sleepiness
📈 PositiveBenzinga•Nov 12, 2025, 12:33 PM
Truist Securities Initiates Coverage On Alkermes with Buy Rating, Announces Price Target of $50
📈 PositiveBenzinga•Nov 11, 2025, 11:56 AM
Wells Fargo Maintains Overweight on Alkermes, Lowers Price Target to $42
➖ NeutralBenzinga•Oct 29, 2025, 02:16 PM
Needham Maintains Buy on Alkermes, Raises Price Target to $44
📈 PositiveBenzinga•Oct 29, 2025, 09:55 AM
Alkermes Raises FY2025 GAAP EPS Guidance from $1.03-$1.21 to $1.36-$1.47 vs $1.29 Est; Raises FY2025 Sales Guidance from $1.340B-$1.430B to $1.430B-$1.490B vs $1.423B Est
📈 PositiveBenzinga•Oct 28, 2025, 11:07 AM
Alkermes GAAP EPS of $0.49 beats by $0.19, revenue of $394.2M beats by $37.99M
📈 PositiveSeeking Alpha•Oct 28, 2025, 11:07 AM
Alkermes Q3 EPS $0.49 Beats $0.30 Estimate, Sales $394.185M Beat $356.099M Estimate
📈 PositiveBenzinga•Oct 28, 2025, 11:02 AM
Frequently Asked Questions about ALKS
What is ALKS's current stock price?
Alkermes plc (ALKS) is currently trading at $28.45 per share. The stock has moved +2.30% today.
What is the analyst price target for ALKS?
The average analyst price target for ALKS is $47.40, based on 1 analyst.
What sector is Alkermes plc in?
Alkermes plc operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is ALKS's market cap?
Alkermes plc has a market capitalization of $4.70 billion, making it a mid-cap company.
Does ALKS pay dividends?
No, Alkermes plc does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACAD
ACADIA Pharmaceuticals Inc.
$27.16
Mkt Cap: $4.6B
ACLX
Arcellx, Inc.
$63.96
Mkt Cap: $3.5B
AKRO
Akero Therapeutics, Inc.
$54.65
Mkt Cap: $4.5B
ARWR
Arrowhead Pharmaceuticals, Inc.
$68.16
Mkt Cap: $9.4B
CRSP
CRISPR Therapeutics AG
$55.86
Mkt Cap: $4.9B
KYMR
Kymera Therapeutics, Inc.
$83.99
Mkt Cap: $6.0B
PCVX
Vaxcyte, Inc.
$46.42
Mkt Cap: $6.1B
PTCT
PTC Therapeutics, Inc.
$78.57
Mkt Cap: $6.3B
PTGX
Protagonist Therapeutics, Inc.
$86.05
Mkt Cap: $5.4B
TGTX
TG Therapeutics, Inc.
$30.98
Mkt Cap: $4.9B
Explore stocks similar to ALKS for comparison